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A B S T R A C T
Background
Bronchiectasis is a major cause of respiratory morbidity especially in developing countries. In affluent countries, bronchiectasis is
increasingly recognised in certain subsections of communities (e.g. Aboriginal communities) as well as a coexistent disease/comorbidity
and disease modifier in respiratory diseases such as COPD (reported rates of 29-50% in adults). Respiratory exacerbations in people
with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Current
recommendations for inactivated influenza vaccination includes adults aged 65 years and over, those in residential care and health care
workers and also all adults and children with chronic illness, particularly cardiac and pulmonary diseases.
Objectives
To evaluate the effectiveness of influenza vaccine as routine management in children and adults with bronchiectasis in (a) reducing the
severity and frequency of respiratory exacerbations and (b) pulmonary decline
Search methods
TheCochrane Register of Controlled Trials (CENTRAL), theCochrane Airways Group Specialised Register,MEDLINE and EMBASE
databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of influenza were also contacted. The latest
searches were performed in July 2010.
Selection criteria
All randomised controlled trials with at least one annual influenza vaccine involving children or adults with bronchiectasis.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. It was planned that two independent reviewers selected,
extracted and assessed data for inclusion.
Main results
No eligible trials were identified and thus no data were available for analysis.
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Authors’ conclusions
There is neither evidence for, nor against, routine annual influenza vaccination for children and adults with bronchiectasis.
P L A I N L A N G U A G E S U M M A R Y
Influenza vaccine for children and adults with bronchiectasis
In many countries, influenza vaccination is an accepted part of routine immunisation recommendations particularly in persons 65 years
and over, those in long-term care facilities and also adults and children with chronic illnesses including those with bronchiectasis. In this
review however, our search for randomised control trials examining the effectiveness of influenza vaccines for people with bronchiectasis
revealed no relevant studies. In the absence of evidence, patients’ needs should be individualised and national guidelines be adhered to.
B A C K G R O U N D
Bronchiectasis, previously termed an ’orphan disease’ is increas-
ingly recognized as a major cause of respiratory morbidity espe-
cially in developing countries (Karadag 2005, Karakoc 2001) and
in pockets of affluent countries (Singleton 2000, Callahan 2002,
Edwards 2003). The underlying aetiology of bronchiectasis varies
frompost recurrent respiratory infections to rare immune deficien-
cies. A variety of diseases including the common chronic obstruc-
tive pulmonary disease (COPD) (Patel 2004) and less common
respiratory diseases (e.g. bronchiolitis obliterans (Chang 1998)
and sarcoidosis (Lewis 2002)) and even non-primary respiratory
(e.g. autoimmune) diseases may culminate in the development
of bronchiectasis. The presence of bronchiectasis increases the
morbidity and mortality of the underlying primary disease (Patel
2004, Lewis 2002, Keistinen 1997). For example, bronchiecta-
sis has been reported in 29-50% of COPD (Patel 2004, O’Brien
2000) and when present, increases the severity (Patel 2004) and
frequency (Gursel 2006) of respiratory exacerbations. Thus, man-
agement of the symptoms and severity of bronchiectasis is impor-
tant.
The dominant symptoms and signs of bronchiectasis are produc-
tive or wet cough, dyspnoea on exertion and presence of other res-
piratory signs (clubbing, chest wall deformity, respiratory noises
such as wheeze or crepitations on auscultation). In the long term,
pulmonary decline may occur (Keistinen 1997, Twiss 2006). Like
patients with COPD, children and adults with bronchiectasis
also suffer from recurrent acute exacerbations, some of which re-
quire hospitalised treatment. Effective management regimes for
bronchiectasis aim to reduce the frequency and severity of respi-
ratory exacerbations and the rate long term pulmonary decline.
Based on Cole’s ’vicious circle hypothesis’, microbial colonization/
infection is important in the pathophysiology of bronchiectasis
as it leads to bronchial obstruction and a normal or exaggerated
inflammatory response (Cole 1986). Thus treatment modalities
that prevent or limit respiratory infections would prevent or re-
duce respiratory decline. Respiratory infections also increase mor-
bidity and reduces quality of life in those suffering bronchiecta-
sis (Martinez-Garcia 2005). Theoretically prevention of influenza
through the use of influenza vaccine would be a useful routine
managementmodality for children and adults with bronchiectasis.
Indeed yearly influenza vaccination is recommended for patients
with bronchiectasis (Chang 2002).
Both inactivated and live attenuated (LAIV) influenza vaccine are
now available. Both are annually modified trivalent vaccines with
adjustments for each of the major circulating influenza viruses: A
(H3N2), A (H1N1) and B and administered annually (Orenstein
2005). The efficacy is directly related to the degree of concordance
between the virus strains included in the vaccine and the strains
circulating in the community. The inactivated vaccine contains
killed viruses and is administered via intramuscular route and is
recommended in those 6 months and older, in healthy individuals
and those with chronic medical conditions. The newer LAIV con-
tains live virus with potential for replication and is currently only
recommended in healthy individuals aged between 5 and 49 years
(Orenstein 2005), thus contraindicated in those with bronchiec-
tasis.
Current recommendations for inactivated influenza vaccination
includes adults aged 65 years and over, those in residential care and
health care workers and also all adults and children with chronic
illness, particularly cardiac and pulmonary diseases. Influenza vac-
cine has been estimated to be 70-90% effective in preventing in-
fluenza in healthy individuals under 65 years of age, with some
reduction in efficacy in the elderly (Orenstein 2005). A meta-
analysis of 20 cohort studies involving both nursing home pop-
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ulations and community-dwelling elderly estimated effectiveness
of 56%, 53%, 50% and 68% for preventing respiratory illness,
pneumonia, hospitalisation and death, respectively. The efficacy
of influenza vaccination in children is less known, though it has
been estimated to provide 56% or more protection (Orenstein
2005, Fukuda 2004). The effect of influenza vaccine in preventing
asthma exacerbations related to influenza is uncertain in patients
with asthma (Cates 2008). In another Cochrane review, Poole and
colleagues concluded that influenza vaccination reduces respira-
tory exacerbations in patients with COPD (Poole 2006). The ef-
fect size described in the meta-analysis of RCTs was similar to that
of observational studies (Poole 2006).
The triggers for bronchiectasis exacerbations are less well stud-
ied compared to the available data on triggers of exacerbations
for asthma and COPD. The proportion of bronchiectasis exac-
erbations triggered by infections is uncertain, much less the cul-
prit microbiological organism. The effectiveness of influenza vac-
cination for bronchiectasis may thus, be rather different to that
for asthma and COPD. Influenza vaccination may be associated
with local and systemic adverse events including a flu-like illness
(Poole 2006). A systematic review of the effectiveness of influenza
for children and adults with bronchiectasis would be beneficial to
guide clinical practice.
O B J E C T I V E S
To evaluate the effectiveness of influenza vaccine as routine man-
agement in children and adults with bronchiectasis in (a) reduc-
ing the severity and frequency of respiratory exacerbations and (b)
pulmonary decline
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials using influenza vaccine in patients
with bronchiectasis
Types of participants
Children or adults with bronchiectasis (defined clinically or radi-
ologically)
Exclusion criteria: Participants with cystic fibrosis or other diseases
where bronchiectasis is not present
Types of interventions
All randomised controlled trials with at least one annual influenza
vaccine. All types of influenza vaccines were to be included.
Types of outcome measures
It was planned that attempts would have beenmade to obtain data
on at least one of the following outcome measures:
(A) for short-term effectiveness (12 months or less)
a) proportions of participants who had respiratory exacerbations
b) proportions of participants who were hospitalised,
c) total numbers of days with respiratory symptoms
d) total number of hospitalised days
e) mean difference in bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, cough diary, etc),
f ) proportions experiencing adverse effects of the intervention,
(e.g. local reaction, exacerbation immediately post vaccination,
systemic effects (myalgia, fever, fatigue), Gullian-Barre syndrome,
etc)
Outcomes (a) to (e) were to be examined globally as well as also
specifically to proven influenza infections (from swabs or rising
titres)
(B) for medium to long-term outcomes (>1 year)
g) radiology scores (high resolution computed tomography scans
or chest radiograph)
h) lung function
i) clinical indices of bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, etc),
j) relevant airway markers of inflammation.
Search methods for identification of studies
Trials were identified from the following sources:
1. The Cochrane Airways Group Specialised Trials Register
2. The Cochrane Central Register of Controlled Trials
(CENTRAL)
3. MEDLINE (1966 to present). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
4. OLDMEDLINE (1950 to 1965). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
5. EMBASE (1980 to present).Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
6. The list of references in relevant publications.
7. Written communication with the authors of trials would
have been included in the review if necessary.
8. Pharmaceutical companies that manufacture influenza
vaccines.
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The search strategies used in the electronic databases are listed in
Appendix 1. The latest searches were performed in July 2010.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, two reviewers indepen-
dently reviewed literature searches to identify potentially relevant
trials for full review. Searches of bibliographies and texts were con-
ducted to identify additional studies. From the full text using spe-
cific criteria, the same two reviewers independently selected trials
for inclusion. Agreement would have been measured using kappa
statistics. Disagreement would have been resolved by consensus.
Data extraction and management
It was planned that trials that satisfied the inclusion criteria would
have been reviewed and the following information recorded: study
setting, year of study, source of funding, patient recruitment de-
tails (including number of eligible subjects), inclusion and exclu-
sion criteria, other symptoms, randomisation and allocation con-
cealment method, numbers of participants randomised, blinding
(masking) of participants, care providers and outcome assessors,
dose and type of intervention, duration of therapy, co-interven-
tions, numbers of patients not followedup, reasons forwithdrawals
from study protocol (clinical, side-effects, refusal and other), de-
tails on side-effects of therapy, andwhether intention-to-treat anal-
yses were possible. Data would have been extracted on the out-
comes described previously. Further information would have been
requested from the authors when required.
Assessment of risk of bias in included studies
Studies included in the review would have undergone quality as-
sessment performed independently by two reviewers. Four compo-
nents of quality would have been assessed. Risk of bias in included
studies would have been assessed as either high, low or unclear
risk of bias using the Cochrane Collaboration’s risk of bias tool
(Higgins 2008), and the following headings 1) sequence genera-
tion; 2) allocation concealment; 3) blinding; 4) incomplete out-
come data; 5) selective outcome reporting; 6) other bias. While
only the allocation concealment quality assessment would have
been displayed in the meta-analysis figures, all assessments would
have been included in the “Characteristics of included studies”
table. Inter-reviewer reliability for the identification of high qual-
ity studies for each component would have been measured by the
Kappa statistic.
Measures of treatment effect
For the dichotomous outcome variables of each individual study,
odds ratio (OR) would have been calculated using a modified in-
tention-to-treat analysis. This analysis assumes that children not
available for outcome assessment have not improved (and proba-
bly represents a conservative estimate of effect). An initial qualita-
tive comparison of all the individually analysed studies of all the
individually analysed studies examine whether pooling of results
(meta-analysis) is reasonable. This would take into account differ-
ences in study populations, inclusion/exclusion criteria, interven-
tions, outcome assessment, and estimated effect size.
Unit of analysis issues
For cross-over studies, mean treatment differences would have
been calculated from raw data, extracted or imputed and entered
as fixed effects generic inverse variance (GIV) outcome, to provide
summary weighted differences and 95% confidence intervals. In
cross-over trials, only data from the first arm would have been in-
cluded in meta analysis if data were combined with parallel studies
(Elbourne 2002).
Assessment of heterogeneity
Any heterogeneity between the study results would have been de-
scribed and tested to see if it reached statistical significance using
a chi-squared test. The 95% confidence interval estimated using a
random effects model would have been included whenever there
are concerns about statistical heterogeneity.
Data synthesis
It was planned that the results from studies that met the inclu-
sion criteria and reported any of the outcomes of interest would
have been included in the subsequent meta-analyses. The sum-
maryweighted risk ratio and 95%confidence interval (fixed effects
model) would have been calculated (Cochrane statistical package,
Review Manager 5).
Numbers needed to treat (NNT) would have been calculated from
the pooled OR and its 95% CI applied to a specified baseline
risk using an online calculator (Cates 2003). If studies reported
outcomes using different measurement scales, the standardised
mean difference would have been estimated.
Subgroup analysis and investigation of heterogeneity
The following a priori sub-group analyses were planned:
1. children (aged 18 years or less) and adults (>18 years)
2. types of influenza vaccine
3. type of control group
4. participant type (bronchiectasis as primary disease vs
bronchiectasis as co-existent disease)
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5. severity of bronchiectasis (based on lung function)
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. study quality
2. study size
3. variation in the inclusion criteria
4. differences in the medications used in the intervention and
comparison groups
5. differences in outcome measures
6. analysis using random effects model
7. analysis by “treatment received”
8. analysis by “intention-to-treat”
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
The searches identified four potential publications, none fulfilled
the study eligibility criteria. The updated 2010 search identified
103 potential papers, one (Furumoto 2008) was retrieved but was
excluded.
Risk of bias in included studies
Not applicable.
Effects of interventions
The Airways Group specialised register/search identified 289 po-
tentially relevant titles. After assessing the abstracts, four publica-
tions were considered for inclusion into the review including two
non-English articles (French). None of the studies fulfilled study
criteria. No additional studies were found in the review articles.
No additional data were available from the five pharmaceutical
companies contacted (CSL Limited, Sanofi Pasteur Pty Limited,
ChironVaccines Australia Pty Ltd, GlaxoSmithKline Australia Pty
Ltd, Solvay Pharmaceuticals).
D I S C U S S I O N
No randomised controlled trials comparing any influenza vaccines
in children or adults with bronchiectasis were identified.
Based on many rationales including the risk factors of severe in-
fluenza infections, yearly influenza vaccination is widely recom-
mended for patients with chronic respiratory disorders (Cosgrove
2005, Jefferson 2006). However there is no RCT evidence that
has examined whether annual influenza vaccination is indeed ben-
eficial in patients with bronchiectasis. The Cochrane review on
influenza vaccination for patients with COPD described that “in-
activated influenza vaccination has a clinically important and sig-
nificant effect on influenza-related exacerbations, and probably
an effect on the total of exacerbations in COPD patients” (Poole
2006). Given the wide overlap between COPD and bronchiec-
tasis, where up to 50% of patients with COPD have coexistent
bronchiectasis (Patel 2004), it is arguably justified that until new
evidence to the contrary exist, patients with bronchiectasis should
be routinely vaccinated. However influenza vaccinations are not
without risks and adverse events although mostly minor, may be
serious (Wong 2005). Thus, in the absence of good evidence for
the benefits of annual routine influenza vaccination, individual
preferences and risk factors for increased adverse events should be
considered. Furthermore, the argument of policy versus evidence
for influenza vaccination was recently elegantly discussed by Jef-
ferson (Jefferson 2006).
In patientswith asthma andCOPD,Cochrane reviews have shown
that inactivated influenza vaccinations do not cause an immedi-
ate respiratory exacerbation (Cates 2008, Poole 2006). Whether
immediate respiratory exacerbations is increased in patients with
bronchiectasis post inactivated influenza vaccinations is unknown;
it remains a theoretical risk in the context of the common occur-
rence of mild immune dysfunction in patients with bronchiectasis
(King 2006). In the consideration of possible future uses of LAIV
(which is currently used only in healthy individuals and hence not
currently relevant in this target group), the risk of viral shedding
for several days, especially in children (Cosgrove 2005) must also
be taken into account.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is neither evidence for nor against, routine annual in-
fluenza vaccination for children and adults with bronchiectasis
from randomised controlled trials. Given the recommendations
of the Cochrane review on influenza vaccination in patients with
COPD (Poole 2006), and the significant overlap between COPD
and bronchiectasis, current recommendations for annual influenza
vaccination in patients with bronchiectasis is justified. However,
individual responses and risk for adverse effects need to be taken
into account when considered for routine annual influenza vacci-
nation.
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Implications for research
Acknowledging the difficulty in conducting large, randomised,
placebo-controlled trials of repeated influenza vaccination in pa-
tients with bronchiectasis, it would still appear desirable to do so.
There is also little knowledge on the effects of annual revaccination
in this target group. Multi-centre randomised controlled trials to
establish the efficacy of influenza vaccination in reducing severity
and frequency of respiratory exacerbations and pulmonary decline
in people with bronchiectasis are needed. As responses to vaccines
alters with age, cohorts should comprise of different age groups
including young children (aged under 2 years), children, adults
and older adults. Determining true influenza infections from the
range of other influenza-like illnesses by microbiological and sero-
logical techniques is recommended.
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Hayden 1995 Pilot study to determine whether the use of structured guidelines for which pulmonary disorders warrant influenza
vaccination increases use of vaccinations
King 2005 Observational study in adults with bronchiectasis
Lamotte 1981 Non RCT in French (review article)
Michel 1975 Study on children and adolescents with bronchiectasis using dietary supplements and anti-bacterial vaccine
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D A T A A N D A N A L Y S E S
This review has no analyses.
WH A T ’ S N E W
Last assessed as up-to-date: 19 July 2010.
Date Event Description
19 July 2010 New search has been performed New search. No new studies added.
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 3, 2007
Date Event Description
12 March 2009 Amended Contact details changed.
16 April 2008 Amended Converted to new review format.
18 April 2007 New citation required and conclusions have changed Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
CC and AC wrote the protocol and review, and selected relevant articles from the search. CC wrote to the pharmaceutical companies.
PM reviewed the manuscript.
D E C L A R A T I O N S O F I N T E R E S T
None declared.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Bronchiectasis [∗complications]; Influenza Vaccines [∗administration & dosage]; Influenza, Human [∗prevention & control]
MeSH check words
Adult; Child; Humans
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